Du är här


Medical Marijuana Inc.: Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society f

Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic EncephalopathyKannalife Sciences, Inc., a Phyto-Medical Company(TM) Has Found Through Its Research That KLS-13019 is 50x More Potent and>400-Fold Safer Than CBDSAN DIEGO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC
Pink:MJNA) is pleased to announce that the Company's portfolio investment
company, Kannalife Sciences, Inc. ("Kannalife"), has made a major
breakthrough in the field for cannabinoid therapeutics with the publication
of the body of science behind the new cannabidiol (CBD)-like molecule
KLS-13019. The abstract, as well as the purchase of the full version of the
publication on the "Discovery of KLS-13019" is available online

"We are very excited to see the progress being made at Kannalife toward their
pharmaceutical development of cannabinoid-derived therapeutic agents," states
Dr. Stuart W. Titus, Chief Executive Officer of Medical Marijuana, Inc. "With
the development of KLS-13019, there is potential for orphan drug designation
in Grade 3 hepatic encephalopathy (HE). Pre-clinical studies have led
Kannalife's scientific team to believe KLS-13019 may successfully provide
answers for late-stage HE patients."

Through pre-clinical testing and pharmacokinetic (PK) studies, Kannalife's
findings indicate improvement over CBD's role as a neuroprotectant in both
increased potency and reduction of toxicity. Side-by-side comparisons between
CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over
CBD in oral bioavailability, CNS penetration, blood-plasma concentrations,
and cognitive improvement in pilot murine behavioral models. The published
findings explain that KLS-13019 was 50-fold more potent and>400-fold safer
than cannabidiol (CBD) and exhibited an improved in vitro profile consistent
with improved oral bioavailability.

Titus continues, "The potential for KLS-13019 and its significance stands
beyond its intended target of ameliorating neurodegeneration brought on by
ethanol and ammonium toxicity but also its potential in repairing liver
damage brought on by cirrhosis. A successful clinical trial may also lead to
other important areas such as the use of KLS-13019 as a possible adjuvant as
a long-term solution for drug-induced liver disease."

Drug-induced liver toxicity (DILI) is a common cause of liver injury. It
accounts for approximately one-half of the cases of acute liver failure and
mimics all forms of acute and chronic liver disease. An estimated 1,000 drugs
have been implicated in causing liver disease on greater than one occasion.
Although, with the exception of rare cases, drug-induced liver injury
subsides after cessation of treatment with the drug, this represents an
important diagnostic and therapeutic challenge for physicians.

About Kannalife Sciences, Inc.

Kannalife Sciences, Inc. is a phyto-medical company involved in the research
and development of novel therapeutic agents designed to be neuroprotectants
and immuno-modulators. Kannalife is currently conducting research and
development at the Pennsylvania Biotechnology Center in Doylestown, PA, for
target drug candidates to treat Hepatic Encephalopathy ("HE") and Chronic
Traumatic Encephalopathy ("CTE"). HE and CTE are oxidative stress related
diseases that affect cognitive and behavioral functions. For more
information, visit: www.Kannalife.com.

About Medical Marijuana Inc.

The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier
cannabis and hemp industry innovator, leveraging our team of professionals to
source, evaluate and purchase value-added companies and products, while
allowing them to keep their integrity and entrepreneurial spirit. We strive
to create awareness within our industry, develop environmentally-friendly,
economically sustainable businesses, while increasing shareholder value. For
more information, please visit the company's website at:



These statements have not been evaluated by the FDA and are not intended to
diagnose, treat or cure any disease.


This press release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties. Such
forward-looking statements by definition involve risks, uncertainties and
other factors, which may cause the actual results, performance or
achievements of Medical Marijuana, Inc. to be materially different from the
statements made herein.


Medical Marijuana Inc. does not sell or distribute any products that are in
violation of the United States Controlled Substances Act (US.CSA). These
companies do grow, sell, and distribute hemp-based products and are involved
with the federally legal distribution of medical marijuana-based products
within certain international markets. Cannabidiol is a natural constituent of
hemp oil.

For further information, please contact:

Public Relations contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070

Corporate Contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Marijuana Inc. via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.